Inhaled adenovirus vector vaccine, preparation method therefor and use thereof
Patent Information
- Application Number
- MYPI2025006420
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-20
- Filing Date
- 2024-04-19
- Publication Date
- 2024-10-20
AI Technical Summary
Existing aerosol drug delivery technology has challenges in achieving effective lung concentrations and dose stability, especially due to individual differences caused by low equipment efficiency and non-standardization, making it difficult to generate a strong immune response in the deep respiratory tract.
The recombinant adenovirus vector is used as an aerosol inhalation vaccine. By adjusting the osmotic concentration of solute molecules and excipient ingredients, a preparation of 300-750 mOsmol/kg is prepared, including sugar, salt, metal ion chelating agent and surfactant to ensure the safety of the recombinant adenovirus. Stability and effective permeability, and improve aerosol deposition efficiency by optimizing atomized particle size and aerodynamic characteristics.
It achieves high-level specific antibody production and cellular immune response in the lungs and body, provides painless, safe and effective mucosal immunity, enhances protection against bacteria and viruses, and is particularly suitable for children and the elderly.
Smart Images

Figure PI2025006420_DRAWING_001 
Figure PI2025006420_DRAWING_002 
Figure PI2025006420_DRAWING_003
Abstract
Description
Adenovirus inhalation vaccine and its preparation method and application Technical Field
[0001] The present invention relates to the field of vaccine technology, and specifically to an adenovirus inhalation vaccine and a preparation method and application thereof, and more specifically to a preparation method and application of a recombinant adenovirus vector vaccine for mucosal administration. Background Art
[0002] Since the 1920s, researchers have been experimenting with aerosol-based drug delivery to treat certain diseases. However, due to technical limitations in aerosol generation, inhalation therapy has struggled to achieve the desired effect, and this route of administration has been controversial. However, the inhalation of nebulized aerosols is gaining increasing attention.
[0003] The cylindrical epithelial cells lining the airways of the gastrointestinal tract, nasal cavity, and lung tissue are impermeable to most polypeptides, proteins, and other macromolecules. However, the tiny alveolar epithelial cells deep within the lung airways are permeable to certain macromolecules. Respiratory drug delivery of polypeptides, proteins, and nucleic acids is a rapidly developing new area in drug delivery research. Although aerosol generation technology is still in its developmental stages, respiratory drug delivery of polypeptides, proteins, and nucleic acids holds great promise.
[0004] The advantages and disadvantages of respiratory aerosol immunization: Aerosol respiratory administration is currently attracting considerable research attention, primarily due to its advantages over other immunization routes: convenience, effectiveness, non-invasiveness, and minimal cross-infection. Aerosol inhalation immunization is a promising immunization route, particularly suitable for children and the elderly. It offers unique advantages over nasal instillation, causing no pain or inconvenience to patients, making it easier for them to accept. Molecules that enter the lungs can induce immune responses not only in the local mucosa but also in ectopic mucosa.
[0005] While it's known that lung tissue allows the passage of large molecules, fully understanding the bioavailability of inhaled substances is challenging because the aerosol deposition rate, the dose, the aerosol concentration, and the particle (or droplet) size distribution in the nasopharynx and respiratory tract are crucial factors. Consequently, respiratory drug delivery approaches remain challenging.
[0006] Respiratory aerosol administration requires appropriate technology. Studies have shown that the gastrointestinal tract, nasal cavity and skin mucosa form a strong barrier to the absorption of biologics.
[0007] The aerosol generating device needs to be improved. The rough equipment leads to lower drug concentration and also affects the stability of the dose. Although the deep respiratory tract has a huge surface area (142m2 in adults), the 2While the drug has a high penetration rate and is known to have a high penetration rate, achieving effective drug concentrations in the alveoli remains challenging. Existing aerosol devices are inefficient and lack standardization, resulting in variable dosage stability for different patients. These challenges remain unresolved.
[0008] Summary of the Invention
[0009] The present invention relates to an aerosol inhalation vaccine, and specifically to a recombinant adenovirus vector aerosol inhalation vaccine, a preparation method and an application thereof. The aerosol inhalation vaccine of the present invention can express one or more antigens at the same time. After inhalation mucosal immunization of the body, not only can high-level specific antibodies be produced in the lungs and the body at the same time, but also a very high cellular immune response can be stimulated. In addition, the vaccine of the present invention is an inhalation administration preparation, which can effectively stimulate mucosal immunity and increase the body's third level of protection. The recombinant adenovirus vector vaccine provided by the present invention has good stability, safety, high efficiency and painlessness, and can effectively treat new bacterial and viral infections and recurrence of latent infections.
[0010] In one aspect of the present invention, a nebulized inhalation preparation is provided, comprising an active ingredient, wherein the active ingredient is a recombinant adenovirus expressing an antigen protein, and the osmotic concentration of the solute molecules in the preparation is 300-750 mOsmol / kg; specifically, the osmotic concentration of the solute molecules in the preparation includes but is not limited to 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 700, 725 or 750 mOsmol / kg.
[0011] Preferably, the osmotic concentration of the solute molecules in the preparation is 325-725 mOsmol / kg; specifically, the osmotic concentration of the solute molecules in the preparation includes but is not limited to 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 700 or 725 mOsmol / kg.
[0012] More preferably, the osmotic concentration of the solute molecules in the preparation is 375-625 mOsmol / kg; specifically, the osmotic concentration of the solute molecules in the preparation includes but is not limited to 375, 400, 425, 450, 475, 500, 525, 550, 575, 600 or 625 mOsmol / kg.
[0013] In some embodiments, the solute molecules include sugars, salts, metal ion chelators, protective agents, and / or surfactants.
[0014] In some specific embodiments, the salt content is 25-75 mM, and the salt is selected from at least one or two of sodium chloride, magnesium chloride, hydrohalides, sulfates, nitrates, phosphates, acetates, propionates, oxalates, malate, citrate, citrate, toluene-sulfonate, benzoate, salicylate and para-aminosalicylate.
[0015] In some embodiments, the sugar is selected from at least one or two of sucrose, trehalose, fucose and / or maltose.
[0016] In some embodiments, the sugar content is 20-75 mg / ml; specifically, the sugar content includes but is not limited to 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75 mg / ml.
[0017] In some embodiments, the protective agent is selected from at least one or two of sorbitol, mannitol, erythritol, maltitol, lactitol, and xylitol.
[0018] In some specific embodiments, the content of the protective agent is 20-75 mg / ml; specifically, the content of the protective agent includes but is not limited to 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75 mg / ml.
[0019] In some embodiments, the total content of the sugar, salt and protective agent is less than 500 mM.
[0020] In some specific embodiments, the surfactant is selected from one or more of Tween, Span, and glycerol; preferably, the surfactant is selected from at least one or two of Tween 20, Tween 80, Span 20, and Span 80.
[0021] In some specific embodiments, the concentration of the surfactant is 0.01-5.0 mg / ml; specifically, the concentration of the surfactant includes but is not limited to 0.02 mg / ml, 0.03 mg / ml, 0.04 mg / ml, 0.05 mg / ml, 0.06 mg / ml, 0.07 mg / ml, 0.08 mg / ml, 0.09 mg / ml, 0.1 mg / ml, 0.2 mg / ml, 0.3 mg / ml, 0.4 mg / ml, 0.5 mg / ml, 0.6 mg / ml, 0.7 mg / ml, 0.8 mg / ml, 0.9 mg / ml, 1 mg / ml, 1.5 mg / ml, 2 mg / ml, 2.5 mg / ml, 3 mg / ml, 3.5 mg / ml, 4.0 mg / ml, 4.5 mg / ml, and 5.0 mg / ml.
[0022] In some specific embodiments, the metal ion chelator is selected from: at least one or two of ethylenediaminetetraacetic acid (EDTA), disodium ethylenediaminetetraacetic acid (EDTA-2Na), aminotriacetic acid (also known as nitrilotriacetic acid NTA), diethylenetriaminepentaacetic acid and its salts, citric acid (CA), tartaric acid (TA) and / or gluconic acid (GA).
[0023] In some embodiments, the pH value of the preparation is 1 to 14, specifically, the pH value of the preparation includes but is not limited to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14; preferably, the pH value of the preparation is 5-8, specifically, the pH value of the preparation includes but is not limited to 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6 .4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0; More preferably, the pH value of the preparation is 6-7.5, specifically, the pH value of the preparation includes but is not limited to 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5.
[0024] In some embodiments, the preparation further comprises a buffer; preferably, the buffer is one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid.
[0025] In some embodiments, the concentration of the buffer is 1 to 15 mM; specifically, the concentration of the buffer includes but is not limited to 1, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, and 15.0 mM.
[0026] In some embodiments, the adenovirus is a human adenovirus or a chimpanzee adenovirus.
[0027] Preferably, the adenovirus is one or more human adenoviruses selected from serotype 1 to serotype 57.
[0028] In some specific embodiments, the chimpanzee adenovirus is selected from the group consisting of AdC8, AdC22, AdC30, AdC37, AdC11, AdC3, AdC17, AdC19, AdC31, AdC20, AdC24, Pan1, Pan2, Pan3, AdC16, AdC26, AdC82, AdC5, AdC7, AdC44, AdC38, AdC43, AdC63, AdC147, AdC73, AdC6, AdC55, AdC83, AdC143, AdC144, AdC145, AdC10, AdC28, AdC9, and AdC68; more preferably, the chimpanzee adenovirus is AdC6, AdC7, AdC63, or AdC68.
[0029] In some embodiments, the adenovirus is a replication-defective recombinant adenovirus.
[0030] In some embodiments, the content of the recombinant adenovirus in the preparation is 1×10 8 ~1×10 12 VP / ml, specifically, the content of the recombinant adenovirus in the preparation includes but is not limited to 1×10 8 vp / ml, 2×10 8 vp / ml, 3×10 8 vp / ml, 4×10 8 vp / ml, 5×10 8 vp / ml, 6×10 8 vp / ml, 7×10 8 vp / ml, 8×10 8 vp / ml, 9×10 8 vp / ml, 1×10 9 vp / ml, 2×10 9vp / ml, 3×10 9 vp / ml, 4×10 9 vp / ml, 5×10 9 vp / ml, 6×10 9 vp / ml, 7×10 9 vp / ml, 8×10 9 vp / ml, 9×10 9 vp / ml, 1×10 10 vp / ml, 2×10 10 vp / ml, 3×10 10 vp / ml, 4×10 10 vp / ml, 5×10 10 vp / ml, 6×10 10 vp / ml, 7×10 10 vp / ml, 8×10 10 vp / ml, 9×10 10 vp / ml, 1×10 11 vp / ml, 2×10 11 vp / ml, 3×10 11 vp / ml, 4×10 11 vp / ml, 5×10 11 vp / ml, 6×10 11 vp / ml, 7×10 11 vp / ml, 8×10 11 vp / ml, 9×10 11 vp / ml, 1×10 12 vp / ml; preferably, the content of the recombinant adenovirus in the preparation is 5×10 9 VP / ml.
[0031] In some specific embodiments, the particle size of the aerosol particles of the nebulized inhalation preparation: D90 particle size is 5.0-10.0 μm; specifically, the D90 particle size includes but is not limited to 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 μm.
[0032] Preferably, the D90 particle size is 6.0 μm, 6.1 μm, 6.2 μm, 6.3 μm, 6.4 μm, 6.5 μm, 6.6 μm, 6.7 μm, 6.8 μm, 6.9 μm, 7.0 μm, 7.1 μm, 7.2 μm, 7.3 μm, 7.4 μm, 7.5 μm, 7.6 μm, 7.7μm, 7.8μm, 7.9μm, 8.0μm, 8.1μm, 8.2μm, 8.3μm, 8.4μm, 8.5μm, 8.6μm, 8.7μm, 8.8 μm, 8.9μm, 9.0μm, 9.1μm, 9.2μm, 9.3μm, 9.4μm, 9.5μm, 9.6μm, 9.7μm, 9.8μm, 9.9μm.
[0033] Specifically, the aerodynamic particle size MMAD is 1.5 to 6 μm, preferably 3.0 to 5.0 μm, and more preferably 3.1 μm, 3.2 μm, 3.3 μm, 3.4 μm, 3.5 μm, 3.6 μm, 3.7 μm, 3.8 μm, 3.9 μm, 4.0 μm, 4.1 μm, 4.2 μm, 4.3 μm, 4.4 μm, 4.5 μm, 4.6 μm, 4.7 μm, 4.8 μm, and 4.9 μm.
[0034] In some specific embodiments, the particle size of the aerosol particles of the nebulized inhalation preparation: D50 particle size is 2.0-7.0 μm; specifically, the D50 particle size includes but is not limited to 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0 μm.
[0035] Preferably, the D50 particle size is 2.5-4 μm; preferably, 2.6 μm, 2.7 μm, 2.8 μm, 2.9 μm, 3.0 μm, 3.1 μm, 3.2 μm, 3.3 μm, 3.4 μm, 3.5 μm, 3.6 μm, 3.7 μm, 3.8 μm, 3.9 μm.
[0036] In some specific embodiments, the particle size of the aerosol particles of the nebulized inhalation preparation: D10 particle size is 0.5-2.50 μm, specifically, the D10 particle size includes but is not limited to 0.5, 1.0, 1.5, 2.0, 2.5 μm; preferably, the D10 particle size is 0.7-1.5 μm, specifically, the D10 particle size includes but is not limited to 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 μm.
[0037] In some embodiments, the aerosol NGI FPF (fine particle fraction) particles smaller than 5.39 μm account for no less than 45% of the deposition percentage of the aerosol inhalation preparation.
[0038] Specifically, the aerosol NGI FPF (fine particle fraction) of particles less than 5.39 μm accounts for no less than 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the deposition percentage of the adenovirus vector vaccine inhalation solution, and preferably, the FPF is 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, or 85%.
[0039] Specifically, the aerosol NGI FPF (fine particle fraction) of particles less than 3.30 μm accounts for no less than 15%, 20%, 25%, 30%, 35%, 40%, 45%, 46%, 47%, 48%, 49%, 50%, or 55% of the deposition percentage of the adenovirus vector vaccine inhalation solution. Preferably, the FPF is 25%, 30%, 35%, 40%, 45%, 46%, 47%, 48%, 49%, 50%, or 55%.
[0040] In some embodiments, the aerosol NGI FPF (fine particle fraction) particles smaller than 3.30 μm account for no less than 25% of the deposition percentage of the aerosol inhalation preparation.
[0041] In some specific embodiments, the aerodynamic particle size MMAD is 1.5-6 μm, specifically, including but not limited to 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, and 6.0 μm; preferably, it is 3.0-5.0 μm, specifically, including but not limited to 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, and 5.0 μm.
[0042] In some specific embodiments, the antigen protein expressed by the recombinant adenovirus is derived from a viral or bacterial antigen, which is selected from: HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, Mycobacterium tuberculosis, and one or more of Chlamydia trachomatis.
[0043] Another aspect of the present invention provides a method for preparing any of the above-mentioned preparations, comprising the following steps: preparing a recombinant adenovirus vector encoding a bacterial or viral antigen, and adding a pharmaceutically acceptable excipient.
[0044] In some specific embodiments, the method comprises the following steps: constructing a fusion antigen sequence; constructing a plasmid; and co-transfecting the obtained recombinant adenovirus shuttle plasmid and a backbone plasmid carrying most of the adenovirus genome into a host cell.
[0045] In some specific embodiments, the method further includes the following steps: culturing the host cells; harvesting the replication-deficient recombinant adenovirus released from the host cells; expanding the culture of the recombinant adenovirus; purifying the recombinant adenovirus obtained from the culture; and adding corresponding excipients to the purified recombinant adenovirus to obtain the vaccine.
[0046] Another aspect of the present invention provides a use of any of the above-mentioned aerosol inhalation preparations and any of the above-mentioned methods in preparing vaccines for preventing infectious diseases in mammals.
[0047] In some embodiments, the vaccine is administered via mucosal immunization.
[0048] Preferably, the mucosa includes oral mucosa or respiratory mucosa.
[0049] Preferably, the solvent is sterile water for injection.
[0050] Preferably, the unit dose of the preparation is 0.05-5 ml, preferably, 0.1-1 ml.
[0051] Preferably, the content of the recombinant adenovirus in the preparation combination is 1×10 8 to 10 10 GC / dose, preferably, 1×10 8 to 2×10 10 GC / dose.
[0052] Specifically, the vaccine is a mucosal immune preparation; the mucosal immune preparation is nasal drops, aerosols, sprays, liquid preparations, gels, microspheres, liposomes, suspensions;
[0053] Specifically, the mucosal administration method is nasal inhalation or oral inhalation; preferably, the inhalation administration method is inhalation of a liquid preparation.
[0054] Specifically, the unit dose of the vaccine is 0.05-0.5 ml.
[0055] The beneficial effects of the present invention compared to the prior art are:
[0056] The adenovirus inhalation formulation of the present invention solves the following problems: 1) subcutaneous and intramuscular vaccines cannot induce sustained mucosal and pulmonary immunity; 2) other delivery methods cannot target immune lung macrophages; 3) other delivery methods cannot utilize adenovirus vectors as safe natural type I adjuvants to enhance the immune response of vaccines in the lungs; and 4) they cannot suppress the recurrence of latent infections.
[0057] In one aspect of the present invention, the adenovirus inhalation formulation is administered via respiratory mucosal delivery, which not only improves compliance but also provides a lower dosage than injection, and can produce a triple immune effect of humoral, cellular, and mucosal immunity. The vaccine composition provided by the present invention can be used for primary or booster immunization.
[0058] In one aspect of the present invention, the vaccine, after atomization by suitable equipment, can produce aerosol particles with a uniform particle size between 2 and 10 μm, preferably between 2.0 and 6 μm. These particles can be inhaled through the nasal or oral cavity and reach the lungs, thereby generating a protective immune response throughout the respiratory tract and lungs, enhancing the effective utilization rate and effectiveness of the vaccine.
[0059] In one aspect of the present invention, the adenovirus inhalation formulation of the present invention is stable and can maintain viral activity for a long period of time. BRIEF DESCRIPTION OF THE DRAWINGS
[0060] Figure 1 shows the IFU variation trend of Ad5 preparations with different osmotic pressures in Table 1 at 37°C.
[0061] Figure 2 shows the IFU variation trend of Chadox1 preparations with different osmotic pressures in Table 2 at 37°C.
[0062] Figure 3 shows the IFU variation trend of Ad26 preparations with different osmotic pressures at 37°C in Table 2.
[0063] FIG4 shows the IFU variation trend of sAd36 preparations with different osmotic pressures at 37°C in Table 2.
[0064] FIG5 shows the effect trend of different sugar / salt / protectant systems on viral activity of inhaled adenovirus preparations in Table 3. DETAILED DESCRIPTION
[0065] The present invention will be further described in detail below in conjunction with specific embodiments. The examples provided are only for illustrating the present invention and are not intended to limit the scope of the present invention. The examples provided below can serve as a guide for further improvements by those skilled in the art and are not intended to limit the present invention in any way.
[0066] Unless otherwise specified, the experimental methods in the following examples are conventional methods and were performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials and reagents used in the following examples, unless otherwise specified, were all commercially available.
[0067] Example 1: Recombinant adenovirus vaccine packaging
[0068] 1. Construction and preparation of fusion antigen strains
[0069] (1) Construction of pDC316 plasmid
[0070] The synthesized GFP gene fragment is enzymatically digested and the digested fragment is recovered. Simultaneously, the shuttle plasmid vector of the AdMax adenovirus system is enzymatically digested and the vector is recovered. The fragment is ligated to the vector using homologous recombination, transformed into competent cells, and plated onto a plate. A single colony is streaked and identified by colony PCR. A single positive colony from the streaked plate is then cultured, and the plasmid is extracted and identified by enzymatic digestion. The positive clone identified by enzymatic digestion is sequenced.
[0071] (2) Packaging of recombinant adenovirus
[0072] The shuttle plasmid and the backbone plasmid of the AdMax adenovirus system were packaged by co-transfection to obtain Ad5, Chadox I, Ad26, and sAd36 viruses carrying the GFP gene, respectively.
[0073] Example 2 Study on the osmotic pressure of inhaled adenovirus preparations
[0074] Using histidine as a buffer, an Ad5 inhalation adenovirus preparation was prepared. The osmotic concentration was adjusted with NaCl and the osmotic concentration of the final preparation was tested to study the effect of different osmotic concentrations on the stability of the inhalation adenovirus preparation (37°C - 3 days - 1 week - 2 weeks IFU). The effect of different osmotic concentrations on the lung response of mice was also studied. The specific groups are as follows:
[0075] Table 1. Stability study of inhaled adenovirus (Ad5) formulations at different osmotic concentrations
[0076] The results are shown in FIG1 . The inhaled adenovirus preparations of groups 3-6 had better stability, and the preparations had better stability when the osmotic concentration was 375-725 mOsmol / l.
[0077] Example 3 Effect of osmotic pressure on different adenovirus preparations
[0078] Using histidine as a buffer, Chadox I, Ad26, and sAd36 inhalation adenovirus preparations were prepared. The osmotic concentration was adjusted with NaCl and the final preparation was tested to a concentration of 300-600 (±25) mOsmol / l. The effect of osmotic pressure on different adenovirus preparations was examined. The details are as follows:
[0079] Table 2. Stability study of inhaled adenovirus (Chadox I, Ad26, sAd36) formulations at different osmotic concentrations
[0080] The results are shown in Figures 2-4. The inhaled adenovirus preparations of Chadox I, Ad26, and sAd36 maintained good stability at an osmotic concentration of 375-725 mOsmol / l.
[0081] Example 4 Effects of different sugar / salt / protectant systems on viral activity
[0082] Using histidine as a buffer, an Ad5 adenovirus preparation for inhalation was prepared. The osmotic concentration was adjusted by adjusting the content of salt, sugar, and protective agent to test the effects of different sugar / salt / protective agent systems on the adenovirus preparation for inhalation. The details are as follows:
[0083] Table 3. Study on the stability of different sugar / salt / protectant systems in relation to osmotic concentrations of inhaled adenovirus preparations
[0084] The results are shown in FIG5 , and the stability of the preparations in groups 8-15 is better.
[0085] Example 5 Study on the aerosolized particle size of inhaled adenovirus preparation
[0086] Based on the experimental results of Examples 2-4, the atomization effect of the formulation system was further investigated. The concentration of mist generated when a nebulizer was used for atomization at different osmotic pressures and the particle size distribution were investigated. The vaccine aerosol particle size distribution after the vaccine was atomized by the Aerogen Solo nebulizer was detected using an inhalation preparation particle size detector (Helos-Inhaler, Sympatec GmbH). The inhalation preparation particle size detector can detect parameters such as X10.3, X50.3, X90.3, VMD, optical concentration Copt and Q3≤5.25μm of the aerosol generated by atomization in real time, where X10.3, X50.3, X90.3 represent the cutoff particle sizes of 10%, 50% and 90% of the volume cumulative distribution, respectively, the optical concentration Copt represents the mist concentration generated during the atomization process, VMD represents the volume average particle size, and Q3≤5.25μm represents the cumulative volume proportion of aerosol particles with a particle size of less than 5.25μm. Specifically as follows:
[0087] Table 4. Study on the stability of different sugar / salt / protectant systems in relation to osmotic concentrations of inhaled adenovirus preparations
[0088] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the scope of protection of the present invention.
[0089] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A nebulized inhalation preparation, characterized in that: The preparation contains an effective ingredient, which is a recombinant adenovirus expressing an antigen protein. The osmotic concentration of the solute molecules in the preparation is 325-725 mOsmol / kg.
2. An aerosol inhalation preparation according to claim 1, characterized in that: The osmotic concentration of the solute molecules in the formulation is 375-625 mOsmol / kg.
3. An aerosol inhalation preparation according to claims 1-2, characterized in that: The solute molecules include sugars, salts, metal ion chelators, protective agents and / or surfactants.
4. An aerosol inhalation preparation according to claim 3, characterized in that: The salt content is 25-75mM, and the salts are selected from at least one or two of sodium chloride, magnesium chloride, hydrohalides, sulfates, nitrates, phosphates, acetates, propionates, oxalates, malates, citrates, toluene-sulfonates, benzoates, salicylates and p-aminosalicylates.
5. An aerosol inhalation preparation according to claim 3 or 4, characterized in that: The sugar content is 20-75 mg / ml, and the sugar is selected from at least one or two of sucrose, trehalose, fucose and / or maltose.
6. An aerosol inhalation preparation according to any one of claims 3 to 5, characterized in that: The content of the protective agent is 20-75 mg / ml, and the protective agent is selected from at least one or two of sorbitol, mannitol, erythritol, maltitol, lactitol, and xylitol.
7. An aerosol inhalation preparation according to any one of claims 3 to 6, characterized in that: The total content of the sugar, salt and protective agent is less than 500 mM.
8. An aerosol inhalation preparation according to any one of claims 3 to 7, characterized in that: The surfactant is selected from one or more of Tween, Span, and glycerol; preferably, the surfactant is selected from at least one or two of Tween 20, Tween 80, Span 20, and Span 80.
9. An aerosol inhalation preparation according to any one of claims 3 to 8, characterized in that: The concentration of the surfactant is 0.01-5.0 mg / ml.
10. An aerosol inhalation preparation according to any one of claims 3 to 9, characterized in that: The metal ion chelating agent is selected from at least one or two of ethylenediaminetetraacetic acid (EDTA), disodium ethylenediaminetetraacetate (EDTA-2Na), aminotriacetic acid, diethylenetriaminepentaacetic acid and its salts, citric acid (CA), tartaric acid (TA) and / or gluconic acid (GA).
11. An aerosol inhalation preparation according to any one of claims 1 to 10, characterized in that: The pH value of the preparation is 1-14; preferably, the pH value of the preparation is 5-8; more preferably, the pH value of the preparation is 6-7.
5.
12. An aerosol inhalation preparation according to any one of claims 1 to 11, characterized in that: The preparation further comprises a buffer; preferably, the buffer is one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid; more preferably, the concentration of the buffer is 1 to 15 mM.
13. The aerosol inhalation preparation according to any one of claims 1 to 12, characterized in that: The adenovirus is a human adenovirus or a chimpanzee adenovirus; preferably, the adenovirus is one or more human adenoviruses selected from serotypes 1 to serotypes 57.
14. The aerosol inhalation preparation according to claim 13, characterized in that: The chimpanzee adenovirus is selected from the group consisting of AdC8, AdC22, AdC30, AdC37, AdC11, AdC3, AdC17, AdC19, AdC31, AdC20, AdC24, Pan1, Pan2, Pan3, AdC16, AdC26, AdC82, AdC5, AdC7, AdC44, AdC38, AdC43, AdC63, AdC147, AdC73, AdC6, AdC55, AdC83, AdC143, AdC144, AdC145, AdC10, AdC28, AdC9, and AdC68; more preferably, the chimpanzee adenovirus is AdC6, AdC7, AdC63, or AdC68.
15. The aerosol inhalation preparation according to any one of claims 1 to 14, characterized in that: The adenovirus is a replication-deficient recombinant adenovirus.
16. The aerosol inhalation preparation according to any one of claims 1 to 15, characterized in that: The content of the recombinant adenovirus in the preparation is 1×10 8 ~1×10 12 VP / ml; preferably, the content of the recombinant adenovirus in the preparation is 5×10 9 VP / ml.
17. The aerosol inhalation preparation according to any one of claims 1 to 16, characterized in that: The particle size of the aerosol particles of the nebulized inhalation preparation: the D90 particle size is 5.0-10.0 μm.
18. The aerosol inhalation preparation according to any one of claims 1 to 16, characterized in that: The particle size of the aerosol particles of the nebulized inhalation preparation: the D50 particle size is 2.0-7.0 μm.
19. The aerosol inhalation preparation according to any one of claims 1 to 16, characterized in that: The particle size of the aerosol particles of the nebulized inhalation preparation is: D10 particle size is 0.5-2.50 μm; preferably, D10 particle size is 0.7-1.5 μm.
20. The aerosol inhalation preparation according to any one of claims 1 to 19, characterized in that: The deposition percentage of particles with aerosol NGIFPF (fine particle fraction) smaller than 5.39 μm in the aerosol inhalation preparation is not less than 45%.
21. The aerosol inhalation preparation according to any one of claims 1 to 20, characterized in that: The deposition percentage of particles with aerosol NGIFPF (fine particle fraction) smaller than 3.30 μm in the aerosol inhalation preparation is not less than 25%.
22. The aerosol inhalation preparation according to any one of claims 1 to 21, characterized in that: The aerodynamic particle diameter MMAD is 1.5 to 6 μm; preferably, 3.0 to 5.0 μm.
23. The aerosol inhalation preparation according to any one of claims 1 to 22, characterized in that: The antigen protein expressed by the recombinant adenovirus is derived from a viral or bacterial antigen, which is selected from: HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi hemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, Mycobacterium tuberculosis, and one or more of Chlamydia trachomatis.
24. A method for preparing the aerosol inhalation preparation according to any one of claims 1 to 23, characterized in that: The method comprises the following steps: preparing a recombinant adenovirus vector encoding bacterial or viral antigens, and adding pharmaceutically acceptable excipients.
25. The method according to claim 24, characterized in that The method comprises the following steps: constructing a fusion antigen sequence; constructing a plasmid; and co-transfecting the obtained recombinant adenovirus shuttle plasmid and a backbone plasmid carrying most of the adenovirus genome into a host cell.
26. The method according to claim 25, characterized in that The method also includes the following steps: culturing the host cells; harvesting the replication-deficient recombinant adenovirus released from the host cells; expanding the culture of the recombinant adenovirus; purifying the recombinant adenovirus obtained by culture; and adding corresponding excipients to the purified recombinant adenovirus to obtain the vaccine.
27. Use of the aerosol inhalation preparation according to any one of claims 1 to 23 and the method according to claims 24 to 26 in the preparation of a vaccine for preventing infectious diseases in mammals.
28. The use according to claim 27, characterized in that The vaccine is administered via mucosal immunization; preferably, the mucosa includes oral mucosa or respiratory mucosa.
